GLP-1 RAs, such as exenatide, may thus represents a disease modifying intervention for Alzheimer’s disease, or adjuvant secondary treatment for symptom progression through regulation of chronic inflammation. Here, GCG is linked to early-onset autosomal dominant Alzheimer disease.